An editorial overview of ICH M12 and its implications for DDI strategy
ICH M12 establishes a globally harmonized framework for evaluating pharmacokinetic drug interactions.
Adopted by the ICH Assembly on 21 May 2024, the M12 guideline on Drug Interaction Studies brings greater consistency to the design, conduct, interpretation and reporting of drug–drug interaction (DDI) assessments. Its purpose is not simply procedural alignment: it encourages development teams to build evidence-based DDI strategies that connect early mechanistic findings, predictive modeling and clinical evaluation.
ICH M12 provides a harmonized approach to studies of pharmacokinetic DDIs across ICH regions. By clarifying how to design, conduct and interpret DDI studies, the guideline can reduce regulatory uncertainty and support more consistent decision-making during development.
The framework addresses interactions mediated by metabolic enzymes and transporters and considers how evidence from nonclinical studies, modeling and clinical investigations can be integrated into an overall DDI risk assessment.
The guideline emphasizes in vitro studies to identify interaction potential early in development, followed by appropriately justified clinical evaluation when needed. It covers both metabolism-mediated and transporter-mediated interactions.
A more standardized evidence framework can reduce avoidable variability and regulatory complexity, allowing development teams to focus resources on the questions that matter most for patient safety and program decisions.
Physiologically based pharmacokinetic (PBPK) models can help integrate drug properties, physiological parameters and interaction mechanisms to predict DDI risk and inform whether additional clinical evaluation is warranted.
The value of M12 lies in making DDI assessment more deliberate and connected across discovery, clinical pharmacology and regulatory strategy. It encourages teams to address interaction mechanisms before they become late-stage development constraints.
ICH M12 creates a foundation for more integrated DDI strategies. Several areas may become increasingly important as tools, data sources and therapeutic modalities continue to evolve.
PBPK models, artificial intelligence and machine-learning approaches may help strengthen prediction of DDI risk, prioritize experiments and improve interpretation of complex datasets.
Greater understanding of genetic variation, organ function, comorbidities and concomitant medications may improve DDI risk assessment for individual patient populations.
Electronic health records, patient registries and other real-world data sources may complement traditional development evidence by helping characterize drug use and interaction patterns across diverse populations.
ICH M12 is a significant advance in global harmonization of DDI studies. It supports a development model in which mechanistic evidence, predictive modeling, clinical evaluation and risk management are considered as one connected strategy.
For drug developers, the opportunity is to use this framework to make DDI assessment earlier, more evidence-led and more informative for both development decisions and patient safety.
PREV：There's no more
2026-07-29
2024-11-01
2024-07-17
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
